Article – Enabling Cost-Effective, Rapid Access to RA Vaccines and Therapeutics with z- dbDNA
As the global demand for RNA-based therapeutics and vaccines accelerates, traditional plasmid DNA (pDNA) production methods often struggle to meet today’s biopharmaceutical landscape’s scalability and efficiency requirements. Touchlight’s z- dbDNA technology delivers a groundbreaking alternative, enabling rapid, high-quality RNA manufacturing with unmatched purity and scalability.
This article explores how Touchlight’s z- dbDNA transforms RNA vaccine and therapeutic development, offering a cost-effective, efficient solution to empower innovation across mRNA, self-amplifying RNA (saRNA), and more.
What You’ll Learn:
- How Touchlight’s z- dbDNA overcomes challenges in RNA manufacturing
- The benefits of synthetic DNA for RNA-based therapeutics
- Why Touchlight’s z- dbDNA is ideal for scalable mRNA and saRNA production
Author – Lisa Caproni, Ph.D., Associate Director of Applications
Access the article here:
About doggybone DNA (dbDNA™)
Doggybone or dbDNA™ is linear, double stranded, covalently closed DNA vector which is produced in an enzymatic manufacturing process. It can incorporate a gene of interest from 600bp to >20kb making it very flexible to support a range of genetic medicines.